Kura Oncology's ziftomenib shows promise in AML treatment, with FDA Priority Review ahead. Read here for an analysis of KURA ...

Archer-Daniels-Midland navigates challenges like weak soybean margins and trade tensions with cost cuts and diversification.

Overweight position in the CMBS sector, particularly the AAA Agency subcomponent, was accretive to the NYLI Short Term Bond ...

Meta's AI investments, open-source strategy, and Zuckerberg's bold vision position it as a leader against OpenAI & Google.